Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 32473126
Wong PP, et al. (2020) Cancer Burden Is Controlled by Mural Cell-β3-Integrin Regulated Crosstalk with Tumor Cells. Cell 181, 1346-1363.e21 32473126
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S122-p - Akt1 (mouse)
Modsite: EEtMDFRsGsPsDNs SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S122‑p, Akt1 iso2 (human): S60‑p, Akt1 (mouse): S122‑p, Akt1 (rat): S122‑p, Akt1 (fruit fly): M234‑p, Akt1 (cow): S122‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F10
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ITGB3 (human) decrease ITGB3 deletion increases

S129-p - Akt1 (mouse)
Modsite: sGsPsDNsGAEEMEV SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S129‑p, Akt1 iso2 (human): S67‑p, Akt1 (mouse): S129‑p, Akt1 (rat): S129‑p, Akt1 (fruit fly): E241‑p, Akt1 (cow): S129‑p
Characterization
Methods used to characterize site in vivo mass spectrometry
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F10
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ITGB3 (human) decrease ITGB3 deletion increases

S473-p - Akt1 (mouse)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F10
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ITGB3 (mouse) decrease ITGB3 deletion increases
cilengitide increase
PF 573228 ITGB3 (mouse) augment treatment-induced decrease
PHA-665752 ITGB3 (mouse) augment treatment-induced decrease
LY294002 ITGB3 (mouse) augment treatment-induced decrease
Met (mouse) ITGB3 (mouse) inhibit treatment-induced decrease Met KO augments

S534-p - NFkB-p65 (mouse)
Modsite: sGDEDFssIADMDFS SwissProt Entrez-Gene
Orthologous residues
NFkB‑p65 (human): S536‑p, NFkB‑p65 (mouse): S534‑p, NFkB‑p65 (rat): S535‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  melanoma skin cancer
Relevant cell lines - cell types - tissues:  B16F10
Cellular systems studied:  cell lines
Species studied:  mouse
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
cilengitide increase
ITGB3 (mouse) decrease ITGB3 deletion increases
PF 573228 ITGB3 (mouse) augment treatment-induced decrease
PHA-665752 ITGB3 (mouse) augment treatment-induced decrease
LY294002 ITGB3 (mouse) augment treatment-induced decrease
IkB-alpha (mouse) ITGB3 (mouse) augment treatment-induced increase